Please check your internet connection and try again.
# Ecospirin 250/75 enteric-coated (Aspirin)
## Overview
Ecospirin 250/75 is a combination product containing enteric-coated aspirin (acetylsalicylic acid). Enteric coating is designed to delay the dissolution of the tablet until it reaches the small intestine, which may reduce gastric irritation.
## Primary Indications
* Cardiovascular risk reduction (secondary prevention of myocardial infarction and stroke in patients with established cardiovascular disease).
* Pain and fever management (though lower doses are typically used for antiplatelet effects, higher doses are used for analgesia/antipyresis).
## Adult Dosing
* **Cardiovascular Risk Reduction:** The typical dose is 75 mg to 150 mg once daily. The specific strength in Ecospirin 250/75 (75 mg aspirin) falls within this range.
* **Analgesia/Antipyresis:** Doses typically range from 325 mg to 650 mg every 4-6 hours as needed. **Ecospirin 250/75 is NOT typically used for acute pain or fever management due to its fixed low dose and enteric coating which delays absorption.**
## Pediatric Dosing
* Aspirin is generally **contraindicated** in children and adolescents with viral infections (e.g., influenza, chickenpox) due to the risk of Reye's syndrome.
* There is no established pediatric dose for Ecospirin 250/75 for its primary indications.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Higher doses may require dose adjustment or increased monitoring.
* **Hepatic Impairment:** Use with caution.
## Contraindications
* Known hypersensitivity to aspirin, salicylates, NSAIDs, or any component of the formulation.
* History of aspirin-induced asthma, urticaria, or other allergic-type reactions.
* Active peptic ulceration or recent gastrointestinal bleeding.
* Bleeding disorders.
* Severe renal or hepatic impairment.
* Children and adolescents with viral infections.
## Adverse Effects
* **Common:** Gastrointestinal upset (dyspepsia, heartburn, nausea), increased bleeding risk (bruising, epistaxis, menorrhagia).
* **Serious:** Gastrointestinal bleeding, ulceration, perforation, tinnitus, hearing loss, Reye's syndrome (in children/adolescents), hypersensitivity reactions (including bronchospasm).
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs, SSRIs, SNRIs:** Increased risk of gastrointestinal bleeding.
* **Corticosteroids:** Increased risk of gastrointestinal ulceration and bleeding.
* **Methotrexate:** Increased toxicity of methotrexate.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** May decrease antihypertensive efficacy and increase risk of renal impairment.
* **Uricosuric agents (e.g., probenecid):** May reduce the efficacy of uricosuric agents.
* **Alcohol:** Increased risk of gastrointestinal irritation and bleeding.
## Monitoring
* Signs and symptoms of gastrointestinal bleeding (e.g., melena, hematemesis, abdominal pain).
* Signs and symptoms of bleeding elsewhere (e.g., bruising, prolonged bleeding from cuts).
* Tinnitus or hearing changes.
* Renal and hepatic function, particularly in patients with pre-existing impairment or those on long-term therapy.
## Clinical Pearls
* The enteric coating delays absorption, meaning it is not suitable for acute pain or fever relief where rapid onset is desired.
* It is crucial to counsel patients on the increased risk of bleeding, especially when combined with other medications or alcohol.
* Patients should be advised to swallow tablets whole and not to crush, chew, or break them to maintain the integrity of the enteric coating.
* Discontinue aspirin at least 5-7 days before elective surgery.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the current prescribing information and relevant guidelines for complete and up-to-date details before making any clinical decisions.
